Article Text

Download PDFPDF
Curcumin against hepatitis C virus infection: spicing up antiviral therapies with ‘nutraceuticals’?
  1. Eve-Isabelle Pécheur
  1. Correspondence to Dr Eve-Isabelle Pécheur, Pathogenesis of Hepatitis B and C Infections, UMR Inserm U1052/CNRS 5286, CRCL, University of Lyon, 151 cours Albert Thomas, 69424 Lyon cedex 03, France; eve-isabelle.pecheur{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Infection with the HCV is one of the major causes of chronic liver disease with an estimated 184 million persons worldwide positive for HCV antibodies1 and 3–4 million newly infected each year. The situation is worrying in emerging countries of Central and Southeast Asia, North Africa and Middle East with seroprevalence around 3%–5%. Central Africa and Egypt remain regions of very high endemicity with a 25% prevalence in the latter. Hepatitis C is therefore a global health problem with striking inequalities in the access to healthcare and implementation of treatments between world regions.

HCV is an enveloped RNA virus classified into seven genotypes, and virions are found associated to β-lipoproteins in the serum of patients.2 A generally asymptomatic initial infection phase is followed by signs of liver injury after 20–30 years, and patients develop cirrhosis or hepatocellular carcinoma in severe cases for which liver transplantation (LT) is the only alternative. In the absence of preventive vaccine, the current standard of care treatment relies on a combination of interferon α (IFNα) and ribavirin, to which direct-acting antivirals (DAA) have been recently added. DAA target viral enzymes of the replication complex and raise great hopes of eradication in treated patients. At present, filed DAA are only effective on genotype 1, induce viral resistance and severe adverse effects, and their costs are out of reach for patients of emerging countries.3 Novel DAA currently in clinical trials are pan-genotypic and usable in IFN-free regimens in a near-future perspective of all-oral therapies.3 HCV-positive patients undergoing LT experience graft infection and recurrence of hepatitis C, shortening their survival compared with uninfected transplant recipients.4 In these particular clinical cases, antiviral therapies aimed at preventing …

View Full Text


  • Funding EIP is supported by the ANRS (Agence Nationale pour la Recherche sur le SIDA et les hépatites virales) and by FINOVI (Fondation Innovation pour l'Infectiologie).

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles